ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Bill & Melinda Gates Medical Research Institute will license an experimental tuberculosis vaccine from GlaxoSmithKline. An existing TB vaccine protects infants and children but not adolescents or adults. The institute plans to further develop the vaccine, M72/AS01E, which recently helped cut TB infections in half in a Phase II clinical trial of HIV-negative adults. The AS01E adjuvant used in the vaccine is also used in GSK’s herpes zoster vaccine, Shingrix.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter